1 Non-Metastatic Axillary Lymph Nodes Have Distinct Morphology and

2 Immunophenotype in Obese Breast Cancer patients at Risk for

3 Metastasis

4 Qingyuan Song^{1†}, Kristen E. Muller^{2†}, Liesbeth M. Hondelink³, Roberta M. diFlorio-Alexander⁴, Margaret Karagas⁵,

- 5 Saeed Hassanpour^{1,5,6}*
- 6
- ¹Department of Biomedical Data Science, Dartmouth College, 1 Medical Center Drive, HB 7261, Lebanon, NH,
 03756, USA
- ⁹ ²Department of Pathology, Dartmouth-Hitchcock Medical Center, 1 Medical Center Drive, Lebanon, NH, 03756,
- 10 USA
- ³Department of Pathology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
- ⁴Department of Radiology, Dartmouth-Hitchcock Medical Center, Geisel School of Medicine at Dartmouth,
- 13 Dartmouth Cancer Center, 1 Medical Center Drive, Lebanon, NH, 03756, USA
- ⁵Department of Epidemiology, Dartmouth College, 1 Medical Center Drive, Lebanon, NH, 03756, USA
- ⁶Department of Computer Science, Dartmouth College, Hanover, NH, 03755, USA
- 16
- 17 Corresponding Author:
- 18 Saeed Hassanpour, PhD
- 19 One Medical Center Drive, HB 7261
- 20 Lebanon, NH 03756
- 21 Email: <u>Saeed.Hassanpour@dartmouth.edu</u>
- 22
- [†]These authors contributed equally to this work
- 24 *Corresponding author
- 25

26 Abstract

27 Obese patients have worse breast cancer outcomes than normal weight women including a 50% 28 to 80% increased rate of axillary nodal metastasis. Recent studies have shown a potential link 29 between increased lymph node adipose tissue and breast cancer nodal metastasis. Further 30 investigation into potential mechanisms underlying this link may reveal potential prognostic 31 utility of fat-enlarged lymph nodes in breast cancer patients. In this study, a deep learning 32 framework was developed to identify morphological differences of non-metastatic axillary nodes 33 between node-positive and node-negative obese breast cancer patients. Pathology review of the 34 model-selected patches found an increase in the average size of adipocytes (p-value=0.004), an 35 increased amount of white space between lymphocytes (p-value<0.0001), and an increased 36 amount of red blood cells (p-value<0.001) in non-metastatic lymph nodes of node-positive breast 37 cancer patients. Our downstream immunohistology (IHC) analysis showed a decrease of CD3 38 expression and increase of leptin expression in fat-replaced axillary lymph nodes in obese node-39 positive patients. In summary, our findings suggest a novel direction to further investigate the 40 crosstalk between lymph node adiposity, lymphatic dysfunction, and breast cancer nodal 41 metastases.

42 Introduction

Breast cancer is the most prevalent cancer in women worldwide, and it is one of the leading
causes of death in women^{1,2}. Obesity, currently affecting over 30% adult females in the United
States³, significantly increases the incidence and worsens the prognosis of breast cancer patients,
among all breast cancer subtypes^{4,5}. Specifically, obese women are 50-80% more likely to
develop axillary metastasis⁴⁻⁶ and have higher breast-cancer specific mortality than normal
weight women⁷.

49

50 The interaction between obesity, immunity, and breast cancer progression is complex, and the 51 understanding of this link is an evolving field of research. Studies have demonstrated an 52 increased risk of poor cancer prognosis among obese patients with ectopic fat within organs such as liver, muscle, and heart $^{8-10}$. Enlarged adipocytes within ectopic fatty depots leads to the 53 54 secretion of pro-inflammatory cytokines and metabolic dysregulation that creates a tumorpermissive micro-environment⁶. In particular, leptin has been identified as an adipokine that is 55 increased in breast cancer patients^{11,12}. The adipocyte-rich environment can also provide local 56 fatty acids to fuel tumor growth^{13,14}. With the prevalence of obesity rapidly increasing in almost 57 all countries¹⁵, further investigation of the underlying mechanisms that put obese patients at an 58 59 increased risk for axillary nodal metastases is crucial. Findings could support the evaluation of 60 lymph node fat content in the workup of breast cancer patients and may inform prognosis, 61 personalized treatment strategies and future targeted therapies.

63 As was recently shown by Almekinders et al, peritumoral breast hyperadiposity results in local 64 steroid hormone biosynthesis and endocrine dysregulation, and is a potentially strong prognostic biomarker for invasive breast cancer in patients with ductal carcinoma in situ (DCIS)¹⁶. Prior 65 66 studies have shown that non-metastatic axillary nodes may be enlarged by excess hilar fat deposition and are more commonly seen in women with obesity^{17,18}. Fat-enlarged non-metastatic 67 axillary lymph nodes identified on mammography and breast MRI are associated with a high risk 68 69 of axillary metastasis in obese patients with invasive breast cancer, and this association is maintained when adjusting for patient and tumor characteristics¹⁹. Our hypothesize is that, 70 71 hyperadiposity and micro-immune dysregulation may also occur in axillary nodal adiposity, 72 creating a pre-metastatic niche for nodal metastases in women with invasive breast cancer. Our 73 study aimed to investigate whether there are changes in the morphology and immunophenotype 74 of nodal hyperadiposity and the immune microenvironment in non-metastatic axillary lymph 75 nodes that are associated with lymph node metastasis in breast cancer.

76

77 Methods

78 We developed and trained a deep learning (DL) framework to identify differences in 79 morphological patterns in non-metastatic axillary lymph nodes from node-positive and node-80 negative patients. The DL model evaluated scanned whole slide images (WSI) of hematoxylin 81 and eosin (H&E) stained slides using a histological image feature extractor to learn interpretable 82 morphological patterns that may be shed light on underlying structural changes that contribute to 83 the increased risk of nodal metastases in obese patients. We also accessed possible alterations of 84 lymphatic, lipid and metabolic-related protein expression related to nodal metastasis through a 85 detailed immunohistochemistry (IHC) analysis.

86

87 Study Population and Data Collection

- 88 The study included obese patients (BMI > 30 kg/m^2) with histologically confirmed invasive
- 89 breast cancer who underwent sentinel lymph node excision (SLN) or axillary lymph node
- 90 dissection (ALND) at Dartmouth-Hitchcock Medical Center (DHMC), Lebanon, NH. A total of
- 91 180 breast cancer cases were identified, including 88 patients with axillary nodal metastasis
- 92 (labeled as node-positive) and 92 patients without nodal metastasis (labeled as node-negative).
- 93 Patients' demographics, clinical, and pathological information including age and BMI at the time
- 94 of cancer diagnosis, tumor size, tumor grade, hormone receptor and HER2 status, and the
- 95 presence of lymphovascular invasion (LVI) were collected from electronic medical records
- 96 (Table 1). All patients included in this study did not receive neo-adjuvant treatment, including
- 97 chemotherapy, prior to surgery. The detailed data collection workflow is illustrated in
- 98 Supplementary Figure 1.
- 99

	1		
	Overall	Node Negative	Node positive
	Overall	Node-Negative	Node-positive
n	180	92	88
Age (years), mean (SD)	60.9 (11.0)	62.1 (9.9)	59.6 (11.9)
BMI, mean (SD)	36.4 (5.8)	36.5 (6.1)	36.3 (5.6)
Tumor Grade, n (%)			
1	26 (14.9)	17 (19.5)	9 (10.2)
2	94 (53.7)	43 (49.4)	51 (58.0)
3	55 (31.4)	27 (31.0)	28 (31.8)
Tumor Size, mean (SD)	28.5 (23.6)	24.1 (19.6)	32.8 (26.4)
Molecular Subtypes, n (%)			
ER+ and/or PR+, HER2-	151 (84.8)	74 (82.2)	77 (87.5)

100 Table 1. Study cohort characteristics

HER2+	11 (6.2)	3 (3.3)	8 (9.1)
TNBC	16 (9.0)	13 (14.4)	3 (3.4)
LVI, n (%)			
Absent	96 (55.5)	66 (76.7)	30 (34.5)
Present	77 (44.5)	20 (23.3)	57 (65.5)

101 Abbreviations: SD – standard deviation; ER – estrogen receptor; PR – progesterone receptor; HER2 –

human epidermal growth factor receptor 2; TNBC – triple-negative breast cancer; LVI – lymphvascular
 invasion.

104

105 WSI of Axillary Lymph Nodes

106 Breast cancer patients underwent SLN or ALND at the time of their breast cancer surgery(partial 107 or full mastectomy). Lymph nodes received from breast cancer patients were grossed according 108 to standard procedures; all nodes were dissected longitudinally into 2 mm increments and 109 submitted completely for histologic evaluation of metastatic disease. Tissue is formalin fixed and 110 embedded into paraffin blocks (FFPE), sliced at 5-micron sections and stained with Hematoxylin 111 and Eosin (H&E) for microscopic evaluation. The lymph node slides were retrieved and 112 reviewed by a board-certified anatomic pathologist who specializes in breast pathology (KEM). 113 For both study sets (node-positive and node-negative groups), only the non-metastatic lymph 114 nodes were chosen for evaluation. Lymph nodes with metastatic foci of cancer were excluded 115 from the dataset. The slides were scanned using the Leica Aperio-AT2 scanner (Leica Biosystem, 116 IL, USA) at 20x and stored in SVS image format. A total of 636 WSI (303 node-positive and 333 117 node-negative) were collected.

118

119 Lymph Node Annotation and Patch Extraction from WSI

The data preparation pipeline is illustrated in **Figure 1a**. We manually annotated regions of axillary lymph nodes containing lymphoid tissue and intranodal adipocytes on WSI with ASAP software (Version 1.9; Netherlands, 2018). Patches of 224x224 pixels were extracted from the pathologist-annotated regions at 10x magnification level to reduce the number of resulted patches. A total of 575,906 patches were extracted from the annotated regions from the H&E WSI (251,341 from node-positive patients and 324,565 from node-negative patients).

126

127 DL Framework for Histological Feature Extraction

We trained a DL framework based on previous work including Wulczyn et al.²⁰ and Jiang et al.²¹ 128 129 to classify the patients' breast cancer nodal status using the non-metastatic lymph node 130 histopathology. Given that the number of WSIs per patient varied, the patients' nodal status was 131 assigned to each WSI as the label, and the model was trained to classify each WSI separately. To 132 start, randomly selected patches from each WSI were input into a convolutional neural network (CNN) with a ResNet-18 backbone and with ImageNet-pretrained weights^{22,23}. The patches were 133 134 converted to patch-level feature vectors of size 512, which were then averaged into a WSI-level 135 feature vector. The resulting vector was fed into a 2-layer fully connected neural network (NN), 136 with a hidden layer of 128 neurons and an output size of 2, indicating predictions of node-137 positive and negative classes. Lastly, a SoftMax normalization was applied to the model output 138 to generate a probability score. The WSI was classified as node-positive if the resulting 139 probability score was greater than 0.5, or as negative otherwise. The patient-level classification 140 was determined by averaging the probability scores of all WSIs from the patient, and then 141 converting to average score to a binary outcome using a threshold of 0.5. The model pipeline is

142 illustrated in **Figure 1b**. The detailed model training and evaluation pipeline is shown in

143 Supplementary Materials I.







146 Figure 1. Summary of study design. a) Pathologist's annotation of axillary lymph nodes 147 (circled in blue) and patch extraction from WSI for use in model training. b) A CNN was used to 148 extract image features from random sampled patches from a WSI. The resulted feature vectors 149 were then averaged and fed into a fully connected NN to predict the node-positive probability of 150 the WSI. c) The trained model was applied to each patch to classify their nodal status. Then, the 151 patches were ranked by their model probability score within their label groups. The top-ranked 152 patches were then examined by a pathologist to identify any differences in morphological 153 features between the node-positive and -negative classes. These features were then quantified 154 and evaluated for statistical differences.

155

156

157 Model Visualization and Statistical Analysis of Morphological Features

158 Figure 1c illustrates the process of identifying morphological features from model-selected

159 patches, as well as the quantification and statistical analysis of these features. Specifically, the

160 trained model was applied to all patches from each patient to calculate a patch-level probability

161 score. The 64 most-predictive patches from each patient were selected and grouped by patients'

162 labels for pathologist review. A pathologist (LH), blinded to the patients' labels and nodal status,

163 reviewed the selected patches to search for any distinct histological patterns between these two

164 groups. The visual findings of morphological patterns were subsequently quantified using image

165 processing techniques (Supplementary Materials III). The statistical significance of the

166 difference in the quantified patterns between the two classes was determined by the Mann-

167 Whitney U test, with a statistical significance considered at a p-value of less than 0.05.

168

169 Immunohistochemistry (IHC) of Selected Markers

170 A total of 30 lymph node samples were selected for IHC analysis. Our goal was to select a

171 combination of immunohistochemical stains to evaluate T-cell (CD3) and B-cell (CD20)

172	proportions, fatty acid metabolism (fatty acid synthase (FASN), lipoprotein lipase (LPL), Spot14,
173	and fatty acid translocase (CD36)), and adipose inflammation (leptin, adiponectin, tumor
174	necrosis factor α (TNF α), and interleukin-6 (IL6)). A radiologist selected lymph node samples
175	based on the extent of fat replacement within the lymph nodes using radiologic studies, with 15
176	samples obtained from patients who had positive lymph nodes and 15 from patients who had
177	negative lymph nodes. Specifically, the 15 node-positive samples had high levels of fat
178	replacement, while and 15 node-negative samples had low levels of fat replacement. Briefly,
179	slides were deparaffinized and rehydrated. Primary antibodies against CD3 (Leica Cat# PA0553,
180	Clone LN10), CD20 (Leica Cat# NCL-L-CD20-L26, Clone L26), FASN (Abcam Cat# ab22759,
181	Polyclonal), LPL ²⁴ , Spot14 ²⁵ , CD36 (Abcam Cat# ab133625, Clone EPR6573), leptin (Abcam
182	Cat# ab16227, Polyclonal), adiponectin (Abcam Cat# ab75989, Clone EPR3217), TNF (Abcam
183	Cat# ab220210, Clone TNFA/1172), IL6 (Abcam Cat# ab9324, Clone 1.2-2B11-2G10) were
184	processed and stained according to manufacturers' protocols. The expression level of the IHC
185	stains were digitally quantified; the detailed methodology is described in Supplementary
186	Materials IV.
187	
188	Results
189	
190	DL-Aided Interpretation of Distinct Lymph Node Morphological Features
191	Our DL-model trained on the WSI patches achieved an area under the receiver operating
192	characteristic curve (AU-ROC) of 0.67 (95% CI: 0.59, 0.75) and the detailed model performance
193	is shown in Supplementary Table 2. Through examination of the model-selected predictive
194	patches, pathologists identified notable variations in histological characteristics between node-

195 positive and node-negative cases. These differences were confirmed with our quantification 196 metrics using our image analysis pipeline. The histological features that are considered and 197 quantified in this study include: the number and size of adipocytes, the proportion of white space 198 between the lymphocytes (defined by white space-lymphoid ratio), and the proportion of red 199 blood cells (defined by erythrocyte-lymphoid ratio). The results and some examples of these 200 measurements and analysis are illustrated in **Figure 2**, and further details on the quantification 201 methodology can be found in the **Supplementary Materials III**. Based on this analysis, we 202 found that node-positive patients had significantly larger intranodal adipocytes, with more 203 variation in adjocyte size, compared to node-negative patients (Figure 2a). Additionally, there 204 was a significantly increased proportion of white space between lymphocytes and red blood cells 205 in the lymph node parenchyma of node-positive patients (Figures 2b and 2c). These 206 morphological differences were also significantly distinct between the model-assigned labels 207 (Supplementary Figure 2). In addition, we found a positive correlation between the increase of 208 average size of adipocytes and higher white space-lymphoid ratio with a Pearson's correlation 209 coefficient of 0.26 (p-value < 0.001) (Supplementary Figure 3).



210

211 Figure 2. Distinct morphological characteristics of axillary lymph nodes in node-positive

and node-negative patients. a) Left: example quantification of lymph node adipocyte size in
 fat-enlarged lymph nodes of node-positive and node-negative patients. The largest adipocyte

from each patch was highlighted with orange or blue. Right: Box and whisker plot of the average

size of adipocyte and the standard deviation (SD) of the adipocyte size in node-positive and -

- negative samples. **b**) Left: example quantification of lymphoid white space defined by white
- space-lymphoid ratio (W/L). Right: Box and whisker plot of the W/L ratio in node-positive and -
- negative samples. c) Left: example quantification of red blood cells in lymph node tissue defined
- 219 by erythrocyte-lymphoid ratio (E/L). Right: Box and whisker plot of the E/L ratio in node-
- 220 positive and -negative samples.
- 221

222 Distinct Expression Pattern of IHC Stains in Lymph Node Lymphoid and Adipose Tissue

- 223 Although no statistical significance was observed in IHC analysis, the visual analysis of
- distribution of IHC stains revealed that fat-enlarged lymph nodes from node-positive patients
- displayed a lower ratio between CD3+ and CD20+ cells due to decreased CD3 expression
- 226 (Figure 3a-i). Specifically, the intensity of CD3 and CD20 is significantly positively correlated
- in non-fatty lymph nodes from node-negative samples (Pearson correlation coefficient = 0.83, p-
- value < 0.001), while no significant correlation was found in fat-replaced lymph nodes from
- node-positive samples (Pearson correlation coefficient = 0.28, p-value = 0.30) (**Figure 3a-ii**).
- 230 Figure 3a-iii and 3a-iv show examples of a fat-replaced node from a node-positive patient with
- low CD3+/CD20+, and a non-fat-replaced node from a node-negative patient with high
- 232 CD3+/CD20+.
- 233 Additionally, node-positive patients exhibited a slightly elevated expression of leptin in
- intranodal and perinodal adipose tissue compared to node-negative patients, as demonstrated in
- 235 **Figure 3b**.



a) Expression of CD3 and CD20 in Lymphoid Tissue



238 Figure 3. Distribution of IHC markers in node-positive and node-negative group. a-i)

- 239 Kernel density estimate and boxplot of the distribution of CD3+/CD20+ ratio. a-ii) Correlation
- 240 between CD3 and CD20 expression in node-positive and -negative node with fitted regression
- 241 line. a-iii) A fat-enlarged node from a node-positive patient with low CD3+/CD20+ a-iv) A non-
- fat-replaced node from a node-negative patient with high CD3+/CD20+. b-i) Boxplot of 242 243
- distribution of leptin intensity in node-positive and -negative groups. b-ii) Comparison of leptin
- 244 stain in the adipose tissue of lymph nodes from a node-positive and a node-negative sample.
- 245

246 **Discussion**

247 This study investigated the morphological and immunophenotypic characteristics of non-248 metastatic axillary lymph nodes in relation to the risk of breast cancer nodal metastasis among 249 obese women. Using a cohort of 88 node-positive and 92 node-negative patients, we trained a 250 DL model that identified several morphological features that were distinct in axillary lymph 251 nodes from node-positive patients, including significantly increased average size of adipocytes, a 252 higher proportion of white spaces within lymphoid tissue, and a higher number of erythrocytes 253 within lymphoid tissue. In addition, the IHC analysis of 30 axillary lymph node samples showed 254 visually decreased CD3 staining, lower CD3+/CD20+ ratios, and elevated leptin expression 255 around nodal adipocytes in the fat-enlarged lymph nodes from node-positive patients, compared 256 to that of the normal lymph nodes from node-negative patients. Together, our findings suggest a 257 link between several histological characteristics of fat-enlarged axillary lymph nodes and nodal 258 metastases in breast cancer patients with obesity.

259

260 Patients with obesity have poor breast cancer outcomes that are not fully explained by BMI. 261 Understanding the factors that contribute to variable breast cancer outcomes among obese 262 women is essential for improving prognosis and identifying potential therapeutic targets, 263 ultimately leading to better outcomes for patients. Studies have found that adipose cells can 264 contribute to cancer progression through the release of signaling molecules, extracellular proteins, lipids, and metabolites that support tumor growth and invasiveness²⁶. Although there have many 265 266 studies examining ectopic adipose located in and around organs, there is limited research investigating the impact of ectopic adipose within lymph nodes on cancer outcomes²⁷. A recent 267 268 study found that the presence of enlarged axillary lymph nodes due to fat infiltration as seen on

mammography and breast MRI is correlated with an increased risk of nodal metastasis in obese
patients when adjusting for patient and tumor characteristics²⁸. Our current study identified
distinct histologic features that could contribute to a tumor-promoting adipose microenvironment.
These findings support the prior radiology study, which has shown a strong correlation between
fat-enlarged lymph nodes and nodal metastases.

274

275 We observed a greater average adipocyte size within the axillary lymph nodes of node-positive 276 patients than that of the node-negative patients. Previous research has established a link between 277 adipocyte hypertrophy in obesity and impaired metabolic regulation that promotes cancer 278 progression, partly due to hypoxia of hypertrophic adipocytes that leads to altered adipokine secretion and ensuing inflammation^{29,30}. Our results align with those of Almekinders et al., who 279 280 found a correlation between larger adipocyte size and an elevated risk of invasive breast cancer 281 following DCIS. This underscores the importance of further research on the role of ectopic nodal 282 adiposity in the development breast cancer nodal metastases.

283

284 Metastatic sites are selectively primed by the primary tumor even before the initiation of metastases occurs, resulting in a premetastatic niche that is devoid of cancer cells³¹. Our H&E 285 286 analysis revealed an increased proportion of lymphoid white spaces in lymph nodes from node-287 positive patients, and a positive correlation between lymphoid white spaces and average 288 adipocyte size of the lymph node. Possible theories to account for the increased white space 289 include interstitial fluid caused by impaired lymphatic drainage³², which promotes migration of 290 tumor cells. Another potential explanation is the production of soluble factors, such as protein 291 ligands or extracellular matrix-modifying proteins that are secreted to induce remodeling of

metastatic sites to facilitate seeding, as explained by Follain et al.³³. Dissemination of tumor-292 293 related factors such as cytokines, chemokines, growth factors, matrix metalloproteinases, and 294 extracellular vesicles have been shown to promote dissemination of tumor cells through 295 stimulation of inflammatory cells and angiogenesis and leads to remodeling of the extracellular 296 matrix^{33–35}. We also noted an increased amount of extravasated red blood cells in the nodal tissue 297 in the node-positive group. While speculation, one theory could be linked to the increased shear 298 fluid forces in vessels with circulating tumor cells, while endothelial cell remodeling to promote tumor cell extravasation can provide an explanation for the leaky vasculature³⁶. Vascular leakage 299 300 and immunosuppression, among others, are changes that have been described in the premetastatic niche³¹. We postulate that the increased white space and extravasated red blood 301 302 cells could represent morphologic evidence of preconditioning the premetastatic niche in axillary 303 lymph nodes in obese patients.

304

305 Our downstream IHC analysis identified changes in immune cell populations and adipokine 306 expression, though these results were not statistically significant due to the limited statistical 307 power of the small sample size. CD3 intensity was lower in fat-enlarged nodes which may reflect 308 decreased immune function in fatty nodes, a finding that has been reported in lymph nodes of obese mice^{37,38}. Furthermore, non-metastatic fat-enlarged nodes of patients with nodal metastases 309 310 also showed increased leptin expression. Leptin has been shown to stimulate proliferation, 311 angiogenesis, migration, and metastasis in breast cancer cell lines by activating the oncogenic pathways, and high serum leptin is associated with a 2 to 5 fold increase in breast cancer risk³⁹. 312 313 Therefore, increased leptin expression in fat-enlarged nodes may also be associated with a pre-314 metastatic niche and requires further evaluation through large-scale IHC analysis.

315 This study is a pioneering effort that examined premetastatic morphological changes in lymph 316 nodes in a cohort of obese patients with a focus on fat-enlarged lymph nodes. There are several 317 limitations to our study. This study has a relatively small sample size, in particular the IHC 318 analysis was restricted to a small number of patients due to limited resources. Our data is from a 319 single institution which may introduce bias and chance of overfitting, and thereby limit the 320 generalization of the findings to a larger population. A nested cross-validation approach was 321 employed to mitigate this limitation. Further validation of our findings is necessary through 322 large-scale, multi-center studies that include a diverse patient population and external validation. 323 Our study is also limited by its retrospective design. Histologic images of axillary lymph nodes 324 obtained via sentinel lymph node biopsy or axillary lymph node dissection were only available at 325 the time of the cancer diagnosis. This temporal limitation makes it challenging to establish a 326 causal relationship between the identified lymph node features and the development of nodal 327 metastasis. However, future studies could investigate the relationship between lymph node 328 characteristics related to nodal hyperadiposity and prospective outcomes, including cancer 329 recurrence, distant metastasis, and long-term patient prognosis to further investigate the clinical 330 importance of the identified morphological features.

331

In conclusion, this study identified several histopathological and immunohistochemical features of non-metastatic axillary lymph nodes in relation to breast cancer nodal metastases in obese breast cancer patients. These findings suggest that nodal hyperadiposity and alterations in the immune microenvironment may play a role in forming the pre-metastatic niche. These results emphasize the need for further research into increased lymph node adiposity. Further investigation into features of the fat-enlarged nodes that account for an increased likelihood of

- 338 nodal metastases is warranted. If confirmed with larger studies, fatty axillary lymph nodes may
- 339 serve as a prognostic imaging marker that can be readily assessed in all breast cancer patients.
- 340 This information may inform personalized treatment strategies and targeted therapies in obese
- 341 patients with breast cancer.

343 Funding

- 344 This research was supported in part by grants from the US National Library of Medicine
- 345 (R01LM012837 & R01LM013833), the US National Cancer Institute (R01CA249758) and
- 346 National Institute of General Medical Sciences (P20GM104416).

347 **Competing Interests**

348 The authors declare no competing interests.

349 Ethics Approval and Consent to Participate

- 350 This study, and the usage of human participant data in this project, were approved by the
- 351 Dartmouth-Hitchcock Medical Center Institutional Review Board (IRB) with a waiver of
- 352 informed consent.

353 Author's Contributions

- 354 All authors contributed to the design of the study. KEM was responsible for collecting the
- 355 histological and immunohistochemistry image data, LMH annotated the histology images and
- 356 RdA collected the clinical data. LMH and KEM analyzed and interpreted the histological
- 357 findings. QS cleaned and preprocessed the data, implemented the methods, conducted statistical
- analysis, and wrote the first draft of the manuscript. All authors revised the manuscript and
- 359 verified the presented results. SH supervised the study.

360 Data Availability Statement

361 The datasets used and/or analyzed during the current study are available from the corresponding362 author on reasonable request.

364 **References**

- Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G. Breast cancer. *The Lancet*.
 2021;397(10286):1750-1769. doi:10.1016/S0140-6736(20)32381-3
- 367 2. Harbeck N, Penault-Llorca F, Cortes J, et al. Breast cancer. *Nature Reviews Disease* 368 *Primers*. 2019;5(1):1-31. doi:10.1038/s41572-019-0111-2
- Products Data Briefs Number 360 February 2020. Published February 28, 2020.
 Accessed March 9, 2020. https://www.cdc.gov/nchs/products/databriefs/db360.htm
- 4. Lorincz AM, Sukumar S. Molecular links between obesity and breast cancer. *Endocrine- Related Cancer*. 2006;13(2):279-292. doi:10.1677/erc.1.00729
- Lohmann AE, Soldera SV, Pimentel I, et al. Association of Obesity With Breast Cancer
 Outcome in Relation to Cancer Subtypes: A Meta-Analysis. *J Natl Cancer Inst.* 2021;113(11):1465-1475. doi:10.1093/jnci/djab023
- Devericks EN, Carson MS, McCullough LE, Coleman MF, Hursting SD. The obesity breast cancer link: a multidisciplinary perspective. *Cancer Metastasis Rev.* 2022;41(3):607 625. doi:10.1007/s10555-022-10043-5
- Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal Hormone Therapy and Long-term
 All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized
 Trials. *JAMA*. 2017;318(10):927-938. doi:10.1001/jama.2017.11217
- Kanwal F, Kramer JR, Mapakshi S, et al. Risk of Hepatocellular Cancer in Patients With
 Non-Alcoholic Fatty Liver Disease. *Gastroenterology*. 2018;155(6):1828-1837.e2.
 doi:10.1053/j.gastro.2018.08.024
- 385
 9. Zhang XM, Dou QL, Zeng Y, Yang Y, Cheng ASK, Zhang WW. Sarcopenia as a predictor
 386 of mortality in women with breast cancer: a meta-analysis and systematic review. *BMC*387 *Cancer*. 2020;20(1):172. doi:10.1186/s12885-020-6645-6
- S S, R O, K K, et al. The Prognostic Impact of Pericardial Fat Volumes in Resected Non small Cell Lung Cancer. *Annals of surgical oncology*. 2020;27(2). doi:10.1245/s10434-019 07703-2
- Sánchez-Jiménez F, Pérez-Pérez A, de la Cruz-Merino L, Sánchez-Margalet V. Obesity and
 breast cancer: role of leptin. *Front Oncol.* 2019;9:596. doi:10.3389/fonc.2019.00596
- Belort L, Rossary A, Farges MC, Vasson MP, Caldefie-Chézet F. Leptin, adipocytes and
 breast cancer: Focus on inflammation and anti-tumor immunity. *Life Sci.* 2015;140:37-48.
 doi:10.1016/j.lfs.2015.04.012
- Micallef P, Wu Y, Bauzá-Thorbrügge M, et al. Adipose Tissue—Breast Cancer Crosstalk
 Leads to Increased Tumor Lipogenesis Associated with Enhanced Tumor Growth. *Int J Mol Sci.* 2021;22(21):11881. doi:10.3390/ijms222111881

- Zaidi N, Lupien L, Kuemmerle NB, Kinlaw WB, Swinnen JV, Smans K. Lipogenesis and
 lipolysis: the pathways exploited by the cancer cells to acquire fatty acids. *Prog Lipid Res.*2013;52(4):585-589. doi:10.1016/j.plipres.2013.08.005
- 402 15. Boutari C, Mantzoros CS. A 2022 update on the epidemiology of obesity and a call to
 403 action: as its twin COVID-19 pandemic appears to be receding, the obesity and
 404 dysmetabolism pandemic continues to rage on. *Metabolism*. 2022;133:155217.
 405 doi:10.1016/j.metabol.2022.155217
- 406 16. Almekinders MMM, Schaapveld M, Thijssen B, et al. Breast adipocyte size associates with
 407 ipsilateral invasive breast cancer risk after ductal carcinoma in situ. *NPJ Breast Cancer*.
 408 2021;7:31. doi:10.1038/s41523-021-00232-w
- 409 17. diFlorio Alexander RM, Haider SJ, MacKenzie T, Goodrich ME, Weiss J, Onega T.
 410 Correlation between obesity and fat-infiltrated axillary lymph nodes visualized on 411 mammography. *Br J Radiol.* 2018;91(1089):20170110. doi:10.1259/bjr.20170110
- 412 18. Keshavarz E, Ahangaran A, Pouya EK, Maheronnaghsh R, Chavoshi M, Rouzrokh P.
 413 Effects of Obesity on Axillary Lymph Node Structure: Association of Hilar Fat Deposition
 414 and Alterations in Cortex Width. *Maedica (Bucur)*. 2020;15(1):99-104.
 415 doi:10.26574/maedica.2020.15.1.99
- 416 19. diFlorio Alexander RM, Song Q. Fat-Infiltrated Axillary Lymph Nodes are Associated with
 417 Node Positive Breast Cancer in Obese Patients.
- Wulczyn E, Steiner DF, Xu Z, et al. Deep learning-based survival prediction for multiple
 cancer types using histopathology images. *PLOS ONE*. 2020;15(6):e0233678.
 doi:10.1371/journal.pone.0233678
- 421 21. Jiang S, Zanazzi GJ, Hassanpour S. Predicting prognosis and IDH mutation status for
 422 patients with lower-grade gliomas using whole slide images. *Sci Rep.* 2021;11(1):1-9.
 423 doi:10.1038/s41598-021-95948-x
- 424 22. He K, Zhang X, Ren S, Sun J. Deep Residual Learning for Image Recognition.
 425 *arXiv:151203385 [cs]*. Published online December 10, 2015. Accessed March 3, 2021.
 426 http://arxiv.org/abs/1512.03385
- 23. Deng J, Dong W, Socher R, Li L, Kai Li, Li Fei-Fei. ImageNet: A large-scale hierarchical
 image database. In: 2009 IEEE Conference on Computer Vision and Pattern Recognition.;
 2009:248-255. doi:10.1109/CVPR.2009.5206848
- 430 24. Lupien LE, Bloch K, Dehairs J, et al. Endocytosis of very low-density lipoproteins: an
 431 unexpected mechanism for lipid acquisition by breast cancer cells [S]. *Journal of Lipid*432 *Research*. 2020;61(2):205-218. doi:10.1194/jlr.RA119000327
- 433 25. Wells WA, Schwartz GN, Morganelli PM, Cole BF, Gibson JJ, Kinlaw WB. Expression of
 434 "Spot 14" (THRSP) predicts disease free survival in invasive breast cancer:

435 immunohistochemical analysis of a new molecular marker. Breast Cancer Res Treat. 436 2006;98(2):231-240. doi:10.1007/s10549-005-9154-z 437 26. D'Esposito V, Ambrosio MR, Giuliano M, et al. Mammary Adipose Tissue Control of 438 Breast Cancer Progression: Impact of Obesity and Diabetes. Front Oncol. 2020;10:1554. 439 doi:10.3389/fonc.2020.01554 440 27. Li M, Xian H chun, Tang YJ, Liang X hua, Tang Y ling. Fatty acid oxidation: driver of 441 lymph node metastasis. Cancer Cell International. 2021;21(1):339. doi:10.1186/s12935-442 021-02057-w 443 28. diFlorio-Alexander RM, Song Q, Dwan D, et al. Fat-enlarged Axillary Lymph Nodes are 444 Associated with Node-Positive Breast Cancer in Obese Patients. medRxiv. Published online 445 February 18, 2021:2021.02.17.20246504. doi:10.1101/2021.02.17.20246504 446 29. Stenkula KG, Erlanson-Albertsson C. Adipose cell size: importance in health and disease. 447 American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. 448 2018;315(2):R284-R295. doi:10.1152/ajpregu.00257.2017 449 30. Ye RZ, Richard G, Gévry N, Tchernof A, Carpentier AC. Fat Cell Size: Measurement 450 Methods, Pathophysiological Origins, and Relationships With Metabolic Dysregulations. 451 Endocrine Reviews. 2022;43(1):35-60. doi:10.1210/endrev/bnab018 452 31. Peinado H, Zhang H, Matei IR, et al. Pre-metastatic niches: organ-specific homes for 453 metastases. Nat Rev Cancer. 2017;17(5):302-317. doi:10.1038/nrc.2017.6 454 32. Lent-Schochet D, Jialal I. Physiology, Edema. In: *StatPearls*. StatPearls Publishing; 2022. 455 Accessed January 15, 2023. http://www.ncbi.nlm.nih.gov/books/NBK537065/ 456 33. Bruni D, Angell HK, Galon J. The immune contexture and Immunoscore in cancer 457 prognosis and therapeutic efficacy. Nat Rev Cancer. 2020;20(11):662-680. 458 doi:10.1038/s41568-020-0285-7 459 34. Weber M, Hauschild R, Schwarz J, et al. Interstitial dendritic cell guidance by haptotactic chemokine gradients. Science. 2013;339(6117):328-332. doi:10.1126/science.1228456 460 461 35. Pastushenko I, Brisebarre A, Sifrim A, et al. Identification of the tumour transition states 462 occurring during EMT. Nature. 2018;556(7702):463-468. doi:10.1038/s41586-018-0040-3 463 36. Follain G, Osmani N, Azevedo AS, et al. Hemodynamic Forces Tune the Arrest, Adhesion, 464 and Extravasation of Circulating Tumor Cells. Dev Cell. 2018;45(1):33-52.e12. 465 doi:10.1016/j.devcel.2018.02.015 466 García Nores GD, Cuzzone DA, Albano NJ, et al. Obesity but not high-fat diet impairs 37. 467 lymphatic function. Int J Obes. 2016;40(10):1582-1590. doi:10.1038/ijo.2016.96

- 468 38. Weitman ES, Aschen SZ, Farias-Eisner G, et al. Obesity impairs lymphatic fluid transport 469 and dendritic cell migration to lymph nodes. *PLOS ONE*. 2013;8(8):e70703.
- 470 doi:10.1371/journal.pone.0070703
- 471 39. Tenvooren I, Jenks MZ, Rashid H, et al. Elevated leptin disrupts epithelial polarity and
- 472 promotes premalignant alterations in the mammary gland. *Oncogene*. 2019;38(20):3855-
- 473 3870. doi:10.1038/s41388-019-0687-8
- 474